KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for ClearPoint Neuro (CLPT) over the last 13 years, with Q3 2025 value amounting to $1.3 million.

  • ClearPoint Neuro's Gains from Investment Securities rose 206586.72% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 25044.54%. This contributed to the annual value of $1.4 million for FY2024, which is 688.43% down from last year.
  • ClearPoint Neuro's Gains from Investment Securities amounted to $1.3 million in Q3 2025, which was up 206586.72% from $1.3 million recorded in Q2 2025.
  • ClearPoint Neuro's 5-year Gains from Investment Securities high stood at $1.4 million for Q1 2021, and its period low was $5000.0 during Q1 2023.
  • Moreover, its 5-year median value for Gains from Investment Securities was $128000.0 (2024), whereas its average is $520688.2.
  • As far as peak fluctuations go, ClearPoint Neuro's Gains from Investment Securities plummeted by 9684.4% in 2021, and later surged by 292000.0% in 2024.
  • ClearPoint Neuro's Gains from Investment Securities (Quarter) stood at $57000.0 in 2021, then soared by 489.47% to $336000.0 in 2022, then tumbled by 88.99% to $37000.0 in 2023, then skyrocketed by 127.03% to $84000.0 in 2024, then soared by 1472.83% to $1.3 million in 2025.
  • Its Gains from Investment Securities was $1.3 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.4 million in Q1 2025.